Allergy Therapeutics plc will have to conduct a new U.S. trial of its hay fever allergy vaccine at an additional cost of £10 million (US$20.3 million) after one subject suffered an adverse reaction, causing the FDA to put the trial on hold. This also will delay the launch of the product by 12 months. (BioWorld International)